Studies related to Hexarelin and the Cardiovascular System

Posted by

The topic of this article will revolve around the Hexarelin peptide and the extensive cardiovascular system research it has been a part of.

Hexarelin is a synthetic form of the growth hormone GHRP and has shown potential in affiliated research for providing cardioprotection in animal models. Hexarelin is derived in part from the word hexapeptide, which refers to the fact that the peptide is composed of six amino acids. The second component of its name, a synthetic analog of ghrelin, comes from where it was produced. Hexarelin is a combination of the hormones hexa and ghrelin. Ghrelin made up of twenty-eight (28) different amino acids and has to be acylated to bind to GHS-R1a, may be investigated alongside this peptide, which can be used in a laboratory environment.

One of the factors that is suggested to contribute to cardioprotection is autophagy management. Researchers report Hexarelin to show potential in preventing hypertrophy, cell death, and oxidative stress in heart muscle cells, as suggested by the findings of one research study that examined the function of putative regulating mechanisms and autophagy. By inhibiting mTOR phosphorylation, the Hexarelin peptide seemed to be able to control the upward signals of autophagy. As speculated by the findings of this investigation, the researchers hypothesized that Hexarelin might prevent the hypertrophy of cardiac muscle cells and cell death.

Structure and Weight of the Hexarelin Peptide

Hexarelin has the chemical formula C47H58N12O6 and a molecular weight of 887 grams per mole. Its chemical name is also Hexarelin. Its sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, and its CAS registration number is 140703-51-1. CAS stands for abstract chemical service. [1]

Hexarelin’s Mechanism of Action

Research suggests Hexarelin may work by activating receptors at both the hypothalamus and pituitary levels to enhance GH discharge in animal test subjects. Hexarelin, as suggested by researchers’ hypothesis, may affect the release of growth hormone using the PKC signaling pathway. Through its attachment to GHS-R1a, it might replicate the function of ghrelin. In addition to this, it may bind to the cardiac receptors and stimulates their activity.

Researchers speculate that, like that of other growth hormone-releasing peptides, it would seem that Hexarelin may be capable of releasing adrenocorticotropin as well as prolactin and cortisol. It has been observed by research teams that Hexarelin did not impact whatsoever thyroid-stimulating hormone, luteinizing hormone, insulin-like growth factor-1, follicle-stimulating hormone, or plasma glucose.

Hexarelin Peptide and the Cardiovascular System

As suggested by the findings of several studies, Hexarelin may exhibit some impact on the heart’s tissues, particularly in conditions such as illness or damage. The findings of this study provide data that Hexarelin may have the capacity to reduce the development of lesions in mouse models of atherosclerosis. Hexarelin may directly influence the heart by attaching itself to the CD36 receptor and the GHSR. Studies conducted on rodents suggest that the peptide may protect cardiac cells from harm in heart attack scenarios by binding to these receptors and preventing cells from undergoing programmed cell death (also known as apoptosis). Research suggests giving mice Hexarelin appeared to increase the number of heart cells that survived, decrease the development of malondialdehyde (a sign of heart cell death), and improve cardiac function.

As speculated by findings of another investigation, Hexarelin seemed to reduce the oxidative stress associated with cardiac failure and slow the process of remodeling the heart muscles. A decline in heart function and morbidity are both considered to be symptoms of the remodeling process. [3] 

Because the method that Hexarelin may employ to protect cardiac cells is not unique to the damage process in myocardial infarctions, scientists hypothesize that Hexarelin may be exploited to protect the heart against subsequent injuries. Research conducted on rats suggested the peptide seemed to improve heart function in an animal model of diabetes by changing how myocardial cells handle potassium and calcium.

Hexarelin Peptide and Muscle

Scientists hypothesize that by activating the GHS-R1a, Hexarelin may cause an increase in calcium influx; however, this effect is not produced in skeletal muscle. Researchers have suggested that Hexarelin may increase rats’ isolated skeletal muscle contractility in a notably calcium-independent manner. 

Based on research conducted on rodents using cachexia models, it has been hypothesized that Hexarelin may also protect myocytes by controlling calcium flow and mitochondrial dysfunction. Without functional mitochondria, cells cannot create the energy required to perform their usual functions, ultimately leading to apostasis. 

More study is needed to understand its full potential applications in science. Hexarelinfor sale online is restricted to usage in research and educational institutes. Biotech Peptides is a great resource for licensed researchers. Remember that none of the substances discussed here are approved for ingestion by humans or animals. Compounds used in scientific research should never be used outside of a laboratory. It is forbidden to make a personal introduction of any type. Sales are restricted to verified professionals and active scientists only. This article’s information is meant only for educational purposes.


  1. National Center for Biotechnology Information. PubChem Database. Examorelin CID 6918297. 2020.
  2. Ma Y, et al. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One Journal, 2012.
  3. Wan Z, et al. FAT/CD36 regulates PEPCK expression in adipose tissue. American journal of physiology. Cell physiology, 2013.